MedEquities Realty Trust (NYSE:MRT) – Stock analysts at B. Riley cut their FY2019 earnings estimates for shares of MedEquities Realty Trust in a research note issued to investors on Monday, May 14th. B. Riley analyst B. Maher now anticipates that the financial services provider will post earnings of $1.27 per share for the year, down from their previous estimate of $1.31. B. Riley has a “Buy” rating and a $13.00 price objective on the stock. B. Riley also issued estimates for MedEquities Realty Trust’s FY2020 earnings at $1.31 EPS.
MedEquities Realty Trust (NYSE:MRT) last announced its quarterly earnings data on Thursday, May 10th. The financial services provider reported $0.16 EPS for the quarter, missing the Zacks’ consensus estimate of $0.30 by ($0.14). The business had revenue of $16.72 million for the quarter, compared to analyst estimates of $16.41 million. MedEquities Realty Trust had a return on equity of 6.17% and a net margin of 34.63%.
Shares of MedEquities Realty Trust opened at $10.39 on Wednesday, Marketbeat reports. The stock has a market cap of $326.84 million, a PE ratio of 9.11 and a beta of -0.18. MedEquities Realty Trust has a 52-week low of $10.27 and a 52-week high of $10.43.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 5th. Stockholders of record on Tuesday, May 22nd will be issued a dividend of $0.21 per share. The ex-dividend date of this dividend is Monday, May 21st. This represents a $0.84 annualized dividend and a dividend yield of 8.08%. MedEquities Realty Trust’s dividend payout ratio is 73.68%.
In other news, Director Bluemountain Capital Managemen sold 17,674 shares of MedEquities Realty Trust stock in a transaction dated Friday, May 4th. The stock was sold at an average price of $10.16, for a total transaction of $179,567.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 235,786 shares of company stock valued at $2,435,627. 2.50% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently bought and sold shares of the stock. LSV Asset Management acquired a new stake in MedEquities Realty Trust in the 4th quarter worth approximately $103,000. JPMorgan Chase & Co. bought a new position in MedEquities Realty Trust in the 3rd quarter worth approximately $118,000. MetLife Investment Advisors LLC bought a new position in MedEquities Realty Trust in the 4th quarter worth approximately $120,000. Barclays PLC increased its position in MedEquities Realty Trust by 252.2% in the 1st quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock worth $168,000 after buying an additional 11,469 shares during the period. Finally, UBS Group AG increased its position in MedEquities Realty Trust by 52.3% in the 1st quarter. UBS Group AG now owns 23,234 shares of the financial services provider’s stock worth $244,000 after buying an additional 7,978 shares during the period. Hedge funds and other institutional investors own 89.09% of the company’s stock.
MedEquities Realty Trust Company Profile
MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.
Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.